PTO/SB/06a (05-07)
Approved for use through 09/09/207 OMS 0851-0231
U.S. Patenti and Trademark Office, U.S. DEPARTMENT OF COMMERCE It to a collection of information unless it contrars a valid OMS control number. Under the Paperwork Reduction Act of 1995, no persons are required to

Application Number		10602348				
Filing Date		2003-06-23	Ī			
First Named Inventor	Kazul	hisa Kada				
Art Unit		2616				
Examiner Name Andre		ew Chung Cheung Lee				
Attorney Docket Number		FILIS 15 990A	_			

				Attorn	ey Doc	ket Number		FUJS 15.990A				
					U.S.	PATENTS				Remove		
Examiner Cite Initial* Patent Number Kind Code1		Issue Date Name of Patentee of cited Document			Applicant Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear							
	1											
If you wish	to a	i dd additional U.S. Pater	nt citatio	n inform	ation pl	lease click the	Ac	id button.		Add		
			U.S.P	ATENT	APPL	CATION PUBL	LIC	CATIONS		Remove		
Examiner Cite Initial*		Publication Number Kind Code ¹		Publication Date		Name of Patentee or Applicant of cited Document		Pages,Columns,Lines when Relevant Passages or Relev Figures Appear				
	1											
If you wish	n to a	dd additional U.S. Publi	shed Ap	plication	citatio	n information p	ole	ase click the Ad	d button	Add		
				FOREIG	GN PAT	TENT DOCUM	E	NTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	ment Country Code ²		Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document		e or	vhere Rel	or Relevant	т.
	1	10126418	JP			1998-05-15						
	2	08102739	JP			1996-04-16	F	UJITSU LIMITED				С
If you wish	n to a	dd additional Foreign P	atent Do	cument	citation	information pl	lea	se click the Add	button	Add		_
			NON	I-PATE	NT LITE	RATURE DO	CL	JMENTS		Remove		

	Application Number		10602348		
	Filing Date		2003-06-23		
	First Named Inventor	Kazul	nisa Kada		
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit		2616		
(Not for Submission under or or it 1.50)	Examiner Name	Andre	w Chung Cheung Lee		
	Attorney Docket Numb	ec	FILIS 15 990A		

Examiner Initials*	aminer cite include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), it (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue nupublisher, city and/or country where published.				
	1	Notice of Ground of Rejection with an English translation dated May 25, 2004 from the corresponding Japanese Application No.: JP 10-222975	×		

If you wish to add additional non-patent literature document citation information please click the Add button Add

Examiner Signature Date Considered

EXAMINER SIGNATURE *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04, 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3), 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 5 Applicant is to place a check mark here if English language translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 GFR 1.99)

Application Number		10602348	
Filing Date		2003-06-23	
First Named Inventor	Kazul	hisa Kada	
Art Unit		2616	
Examiner Name Andre		ew Chung Cheung Lee	
Attorney Docket Number		FUJS 15.990A	

CERTIFICATION STATEMENT

Diagra con	37	CFR	1 97	and	1 02	to make	the	annonnista	selection(s)	'n

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filling of the information disclosure statement. Sea 97 CFR 137(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office is a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1/56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1/97(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- _

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/ Dexter T. Chang /	Date (YYYY-MM-DD)	2007-09-25
Name/Drint	Destro T. Ohenn	Designation Number	44.071

This collection of information is required by 3T CFR 1.87 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C. 12.9 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenary (Tifice, U.S. perpartment of Commence, P. 0. Box 1450, Alexandria, V.S.2311-1450, D. ONT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA.22311-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the stacked form related to a petient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is civulating; and (3) the principal purpuse for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or cosmisting your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or cosmisting your submission related to a patient agricultant or patient. If you do not furnish the requested process and the principal principal patients and the principal principal patients and the principal principal patients and the principal patients and the principal patients and the principal patients are patients. The principal patients are provided to the principal patients and the principal patients are patients. The principal patients are principally and the principal patients are principally as a patient of the patients and the principal patients are principally as a patient of the patients and the patients are provided to the patients and the patients are principally as a patient patients are principally as a patient patients and the patients are principally as a principal patient patients. The patients are patients are patients and the patients are patients and the patients are patients and the patients are patients. The patients are patients are patients are patients and the patients are patients and the patients are patients are patients. The patients are patients are patients are patients and the patients are patients are patients are patients. The patients are patients. The patients are patients are patients ar

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these cords.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record perfains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.